These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 39320891)
1. Clinician Willingness to Prescribe Medications for Opioid Use Disorder to Adolescents in Indiana. Aalsma MC; Bell LA; Schwartz K; Ouyang F; Kolak M; Monahan PO; Mermelstein SP; Carson I; Hulvershorn LA; Adams ZW JAMA Netw Open; 2024 Sep; 7(9):e2435416. PubMed ID: 39320891 [TBL] [Abstract][Full Text] [Related]
2. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272 [TBL] [Abstract][Full Text] [Related]
3. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries? Grove LR; Rao N; Domino ME Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey. Lee S; Sun L; Vakkalanka JP Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424 [TBL] [Abstract][Full Text] [Related]
5. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Jones CM; McCance-Katz EF Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876 [TBL] [Abstract][Full Text] [Related]
6. Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements. Christine PJ; Chahine RA; Kimmel SD; Mack N; Douglas C; Stopka TJ; Calver K; Fanucchi LC; Slavova S; Lofwall M; Feaster DJ; Lyons M; Ezell J; Larochelle MR JAMA Netw Open; 2024 Aug; 7(8):e2425999. PubMed ID: 39102264 [TBL] [Abstract][Full Text] [Related]
7. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376 [TBL] [Abstract][Full Text] [Related]
8. Initiation of Buprenorphine in the Emergency Department: A Survey of Emergency Clinicians. Barkley A; Lander L; Dilcher B; Tuscano M West J Emerg Med; 2024 Jul; 25(4):470-476. PubMed ID: 39028232 [TBL] [Abstract][Full Text] [Related]
9. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers. O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286 [TBL] [Abstract][Full Text] [Related]
10. Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians. Rowan K; Shah SV; Binns S; Murphy E; Satorius J; Ghobadi A; Krauss D; Robbins C; Schoebel V; Knudson A; Kepley H; JAMA Netw Open; 2024 May; 7(5):e2411742. PubMed ID: 38758556 [TBL] [Abstract][Full Text] [Related]
11. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review. Pilarinos A; Bromberg DJ; Karamouzian M JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707 [TBL] [Abstract][Full Text] [Related]
12. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. Flanagan Balawajder E; Ducharme L; Taylor BG; Lamuda PA; Kolak M; Friedmann PD; Pollack HA; Schneider JA JAMA Netw Open; 2024 Sep; 7(9):e2434704. PubMed ID: 39316401 [TBL] [Abstract][Full Text] [Related]
13. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership. Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248 [TBL] [Abstract][Full Text] [Related]
14. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails. Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354 [TBL] [Abstract][Full Text] [Related]
15. Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care. Haggerty T; Turiano NA; Turner T; Dekeseredy P; Sedney CL Addict Sci Clin Pract; 2022 Dec; 17(1):72. PubMed ID: 36517926 [TBL] [Abstract][Full Text] [Related]
16. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. Mauro PM; Gutkind S; Annunziato EM; Samples H JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762 [TBL] [Abstract][Full Text] [Related]
17. Why aren't physicians prescribing more buprenorphine? Huhn AS; Dunn KE J Subst Abuse Treat; 2017 Jul; 78():1-7. PubMed ID: 28554597 [TBL] [Abstract][Full Text] [Related]
18. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults. Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949 [TBL] [Abstract][Full Text] [Related]
19. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff. Andraka-Christou B; Atkins D Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757 [TBL] [Abstract][Full Text] [Related]
20. Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. James JR; Gordon LM; Klein JW; Merrill JO; Tsui JI Subst Abus; 2019; 40(1):11-13. PubMed ID: 29578857 [No Abstract] [Full Text] [Related] [Next] [New Search]